Legalize59765 laws
59765 laws
- § 2331. Director of National Intelligence program on use of intelligence resources in efforts to sanction foreign opioid traffickers
- § 2332. Authorization of appropriations
- § 2333. Regulatory authority
- § 2334. Termination
- § 2335. Exception relating to importation of goods
- § 2341. Definitions
- § 2351. Finding; policy
- § 2352. Use of national emergency authorities; reporting
- § 2353. Imposition of sanctions with respect to fentanyl trafficking by transnational criminal organizations
- § 2354. Penalties; waivers; exceptions
- § 334. Seizure
- § 335. Hearing before report of criminal violation
- § 335a. Debarment, temporary denial of approval, and suspension
- § 335b. Civil penalties
- § 335c. Authority to withdraw approval of abbreviated drug applications
- § 336. Report of minor violations
- § 337. Proceedings in name of United States; provision as to subpoenas
- § 337a. Extraterritorial jurisdiction
- § 341. Definitions and standards for food
- § 342. Adulterated food
- § 347a. Congressional declaration of policy regarding oleomargarine sales
- § 347b. Contravention of State laws
- § 1953. Antidrug program
- § 348. Food additives
- § 349. Bottled drinking water standards; publication in Federal Register
- § 350. Vitamins and minerals
- § 350a. Infant formulas
- § 350a–1. Protecting infants and improving formula supply
- § 350b. New dietary ingredients
- § 350c. Maintenance and inspection of records
- § 350d. Registration of food facilities
- § 353d. Process to update labeling for certain generic drugs
- § 354. Veterinary feed directive drugs
- § 355. New drugs
- § 355a. Pediatric studies of drugs
- § 355c. Research into pediatric uses for drugs and biological products
- § 355c–1. Report
- § 355d. Internal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
- § 355f. Extension of exclusivity period for new qualified infectious disease products
- § 355g. Utilizing real world evidence
- § 356d. Coordination; task force and strategic plan
- § 356e. Drug shortage list
- § 356f. Hospital repackaging of drugs in shortage
- § 356g. Standards for regenerative medicine and regenerative advanced therapies
- § 356j. Discontinuance or interruption in the production of medical devices
- § 356l. Advanced manufacturing technologies designation program
- § 356–1. Accelerated approval of priority countermeasures
- § 356–2. Accelerated approval Council
- § 357. Qualification of drug development tools
- § 2000d–4. Federal authority and financial assistance to programs or activities by way of contract of insurance or guaranty